The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $25.19 in the prior trading day, Pacira BioSciences Inc (NASDAQ: PCRX) closed at $24.81, down -1.51%. In other words, the price has decreased by -$1.51 from its previous closing price. On the day, 0.6 million shares were traded. PCRX stock price reached its highest trading level at $25.5 during the session, while it also had its lowest trading level at $24.6.
Ratios:
Our goal is to gain a better understanding of PCRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.52. For the most recent quarter (mrq), Quick Ratio is recorded 1.91 and its Current Ratio is at 2.38. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.55.
On January 30, 2025, Truist Upgraded its rating to Hold which previously was Sell and also upped its target price recommendation from $8 to $25.
Truist Downgraded its Buy to Sell on August 13, 2024, whereas the target price for the stock was revised from $30 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 07 ’25 when BIGAL MARCELO sold 4,912 shares for $23.67 per share. The transaction valued at 116,267 led to the insider holds 11,393 shares of the business.
BIGAL MARCELO bought 4,912 shares of PCRX for $116,279 on Aug 07 ’25. On Jun 04 ’25, another insider, RIKER LAUREN, who serves as the Senior Vice President, Finance of the company, sold 5,578 shares for $26.21 each. As a result, the insider received 146,208 and left with 59,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 1114780288 and an Enterprise Value of 1300319872. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.58 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 1.842 whereas that against EBITDA is 8.208.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.39, which has changed by 0.989575 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $27.64, while it has fallen to a 52-week low of $11.16. The 50-Day Moving Average of the stock is 4.94%, while the 200-Day Moving Average is calculated to be 9.13%.
Shares Statistics:
The stock has traded on average 692.17K shares per day over the past 3-months and 1004530 shares per day over the last 10 days, according to various share statistics. A total of 44.90M shares are outstanding, with a floating share count of 42.94M. Insiders hold about 4.43% of the company’s shares, while institutions hold 116.92% stake in the company. Shares short for PCRX as of 1753920000 were 5694160 with a Short Ratio of 8.23, compared to 1751241600 on 5602013. Therefore, it implies a Short% of Shares Outstanding of 5694160 and a Short% of Float of 18.200001.
Earnings Estimates
As of right now, 5.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.85, with high estimates of $0.94 and low estimates of $0.8.
Analysts are recommending an EPS of between $2.96 and $2.78 for the fiscal current year, implying an average EPS of $2.85. EPS for the following year is $3.35, with 6.0 analysts recommending between $3.94 and $2.82.
Revenue Estimates
5 analysts predict $183.6M in revenue for the current quarter. It ranges from a high estimate of $187.3M to a low estimate of $180.7M. As of the current estimate, Pacira BioSciences Inc’s year-ago sales were $168.57MFor the next quarter, 5 analysts are estimating revenue of $205.49M. There is a high estimate of $209.9M for the next quarter, whereas the lowest estimate is $201.13M.
A total of 6 analysts have provided revenue estimates for PCRX’s current fiscal year. The highest revenue estimate was $754.9M, while the lowest revenue estimate was $734.11M, resulting in an average revenue estimate of $741.76M. In the same quarter a year ago, actual revenue was $700.97MBased on 6 analysts’ estimates, the company’s revenue will be $823.61M in the next fiscal year. The high estimate is $854.5M and the low estimate is $800.8M.
